Marc Carrier

🧠 Diagnosing recurrent VTE is challenging. PREDICTORS study (n=723) showed that existing clinical decision rules (CDRs) identify patients at higher risk and RO recurrence without imaging in ~15% 📊 In low/moderate-risk PE with negative D-dimer: 🟢 0/82 recurrent VTE (0%; 95% CI…

🚨📣 A long-awaited study from my #BantingCanada fellowship examining predictors of recurrent #VTE and anticoagulant-related🩸 #bleeding in patients with cancer was published in #EHJ today to coincide with my live presentation at #ISTH2025‼️ academic.oup.com/eurheartj/adva…

Implementation matters! A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. #ISTH2025 #VTEprevention 🩸📉

🚨 SPECTACULAR RCT at #ISTH2025! Although non-inferiority to CTPA wasn’t shown, a negative SPECT V/Q scan led to low 3-month VTE risk ✅ Supporting the safety of ruling out PE with a SPECT-based algorithm SPECTacular findings indeed! 🫁💥

🩸 WaVE Study Alert! In patients with acute CAT & weight >90kg, weight-based dalteparin (200 IU/kg) appears safe & effective. 🔹 Anti-Xa levels aligned with non-obese patients 🔹 Higher levels seen in those with bleeding Important data to guide dosing in CAT & obesity.…

🩸 New insights from the RENOVE trial (extended duration anticoagulation) at #ISTH2025: 📉 Reduced-dose DOAC is non-inferior in patients with BMI <30, with less bleeding risk. ⚠️ But in patients with BMI ≥30, reduced-dose may be inferior for bleeding and recurrent VTE. ➡️…

📣 ARIVA Trial at #ISTH2025: 🧪 First RCT on antithrombotic therapy post-venous stenting for PTS 🔵 6-month primary patency rate was higher than expected 💊 No added benefit of aspirin + rivaroxaban vs. rivaroxaban alone ahajournals.org/doi/10.1161/CI…

📢 Long-term results from the CELEST trial presented at #ISTH2025: 🧦 No difference in burdensome PTS (~10%) between 25 vs. 35 mmHg ECS after proximal DVT. ✅ Compliance (>50% use) significantly lowers risk. 🔁 Findings reinforce 2-year RCT data. 📌 A placebo-controlled RCT is…

Great provocative SOA by Dr. Eikeilboom: are there settings where warfarin outperforms DOACs in AF?💊 Emerging data suggest lower mortality & better overall clinical benefit in AF with obesity or rheumatic disease, possibly via GAS6 inhibition #ISTH2025 #AF #Thrombosis 📊👇

🩸 Important findings from Dr @IMYanXu at #ISTH2025: Black individuals on extended anticoagulation for secondary VTE prevention had higher rates of major bleeding, including ICH, than White individuals. 🔎 No difference in CRNMB. 📢 Calls for action to address racial…

🧠 #ISTH2025 SCC survey on stroke in cancer patients: 1️⃣ Physicians choose reperfusion strategies differently for patients with vs. without cancer 2️⃣ Antiplatelets remain the most used for secondary prevention regardless of cancer 3️⃣ Major equipoise on workup post-stroke in…

Meta-analysis on GLP-1RA (vs. placebo) and VTE: 🔹 PE rates significantly lower 📉 🔹 VTE rates lower but not statistically significant 🔹 No difference in DVT 🔹 Study design matters: RCTs vs. observational data Accepted for publication in JTH! #ISTH2025 #VTE #GLP1RA #Thrombosis

Come say hello to David Airdrie, our Executive Director at Thrombosis Canada, at Booth 623! 👋 Learn more about our clinical guides, patient resources, and upcoming education initiatives. 📍#ISTH2025 – We’re here to connect! @ThrombosisCan

📉 In a target trial emulation, GLP-1RA use was linked to a ~25% reduction in VTE risk vs. other weight-loss meds. ⚖️ No added benefit vs. bariatric surgery. Important insights on obesity treatment and thrombosis risk! #ISTH2025 #VTE #GLP1RA

📢 Practice-changing data from the Adjust-DVT study! ✅ Age-adjusted D-dimer safely rules out DVT in low/non-high pretest probability patients 📉 Reduces unnecessary ultrasounds 🔍 +17% yield in patients ≥75 years #ISTH2025 #DVT #Thrombosis #LessIsMore

🩸 Clots tend to come back at the same site as the index VTE! Among 708 patients with prior VTE, recurrences often occurred at the same site as the original event, especially ipsilateral DVTs. Familiar symptoms? Trust your clinical instincts. #ISTH2025 #VTE #DVT